- Details
- In a discussion with Andrea Miyahira, Himisha Beltran discusses her team's research on Prostate-Specific Membrane Antigen (PSMA) heterogeneity and regulation in metastatic prostate cancer. The study, led by Martin Bakht, explores the varied levels of PSMA expression in metastases of androgen receptor-positive prostate cancer, as well as the regulation of PSMA in AR-negative and neuroendocrine pros...
|
- Details
- Lorelei Mucci and Daniel George join Alicia Morgans to discuss the IRONMAN registry, the International Registry for Men with Advanced Prostate Cancer. The registry has actively enrolled 3,200 patients with hormone-sensitive or castration-resistant prostate cancer from 14 countries worldwide. The registry includes a diverse population in terms of geography, socioeconomic status, the type of center...
|
- Details
- Michael Haffner and Andrea Miyahira discuss a JCI Insight publication, "Reversible Epigenetic Alterations Mediate PSMA Expression Heterogeneity in Advanced Metastatic Prostate Cancer". The study investigated PSMA expression heterogeneity in advanced metastatic prostate cancer, finding that the expression pattern of PSMA varies significantly between different metastatic sites and patients. They als...
|
- Details
- Neal Shore discusses the EMBARK trial with Alicia Morgans. The study investigated whether enzalutamide plus leuprolide treatment or enzalutamide monotherapy could prolong metastasis-free survival compared with placebo plus leuprolide for men with high-risk biochemical relapse. The study's primary endpoint was met, with patients in the combination arm showing a 58% reduction in the risk of metastas...
|
- Details
- Pedro Barata speaks with Alicia Morgans about his presentations focusing on genetic and germline testing in patients with advanced prostate cancer. Dr. Barata highlights a study that found more than two-thirds of the patient population had not been tested for homologous recombination repair (HRR) mutations, and another analysis of over 8,100 patients with metastatic castration-resistant prostate c...
|
- Details
- Alicia Morgans hosts a discussion with Rahul Aggarwal about his ongoing research on DLL3 targeting BiTE therapy. DLL3 is expressed in an aggressive form of prostate cancer known as neuroendocrine prostate cancer. Dr. Aggarwal's study focuses on using an immunotherapeutic approach to target DLL3, using a compound developed by Amgen that enhances immune response. With 40 patients already enrolled in...
|
- Details
- Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. The trial's primary endpoint was radio...
|
- Details
- In this conversation, Neha Vapiwala joins Alicia Morgans in a conversation on the ECOG-ACRIN EA8191 (INDICATE) phase III trial in progress. In patients with prostate cancer who experience biochemical recurrence, the ECOG-ACRIN EA8191 (INDICATE) trial examines whether patients without PET-detected lesions outside the pelvis benefit from the addition of apalutamide to standard salvage radiotherapy +...
|
- Details
- In this collaborative discussion, Alicia Morgans and Edward (Ted) Schaeffer examine the evolving guidelines for integrating PET imaging into the diagnosis and treatment of prostate cancer. Dr. Schaeffer emphasizes that these NCCN guidelines, which frequently adapt to new medical developments, act as a flexible framework rather than a rigid rulebook. The conversation explores the application of PSM...
|
- Details
- Alicia Morgans and Carsten-Henning Ohlmann discuss the SPARE trial, an exploratory phase two study involving chemo-naive metastatic castration-resistant prostate cancer patients. The trial compares the standard of care - ADT (Androgen Deprivation Therapy) plus abiraterone plus prednisone, versus abiraterone plus prednisone without the continuation of ADT. Preliminary results show no significant di...
|
